Construction of an efficient evaluative instrument for myasthenia gravis: The MG composite

Muscle and Nerve

Volumn 38, Issue 6, 2008, Pages 1553-1562

  Burns, Ted M ^a   Conaway, Mark R ^b   Cutter, Gary R ^c   Sanders, Donald B ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

MG composite; Myasthenia gravis; Outcome measure

Indexed keywords

ARTICLE; ATTITUDE TO CHANGE; BULBAR PARALYSIS; CLINICAL FEATURE; DAILY LIFE ACTIVITY; DISEASE SEVERITY; EYE DISEASE; FUNCTION TEST; HUMAN; MANUAL MUSCLE TEST; MOTOR PERFORMANCE; MUSCLE FUNCTION; MYASTHENIA GRAVIS; MYASTHENIA GRAVIS ACTIVITIES OF DAILY LIVING SCALE; NECK; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUANTITATIVE MYASTHENIA GRAVIS TEST; RESPIRATORY TRACT DISEASE; RISK FACTOR;

ACTIVITIES OF DAILY LIVING; BLEPHAROPTOSIS; DEGLUTITION DISORDERS; DIPLOPIA; DYSARTHRIA; ELECTRODIAGNOSIS; HUMANS; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; NECK MUSCLES; PHYSICAL ENDURANCE; QUALITY OF LIFE; REFERENCE STANDARDS; RESPIRATORY MUSCLES; RETROSPECTIVE STUDIES;

EID: 56749163489     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21185     Document Type: Article

References (17)

1. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998;841:769-772.
2. Barohn RJ. Standards of measurement in myasthenia gravis. Ann N Y Acad Sci 2003;998:432-439.
3. Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005;64:1968-1970.
4. Burns TM, Conaway M, Cutter G, Sanders DB and The Muscle Study Group. Less is more, or almost as much. The development of a fifteen-item quality-of-life instrument for patients with myasthenia gravis. Muscle Nerve 2008 (to be published).
5. Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Periph Nerv System 2007;12:210-215.
6. Hobart JC, Cano SJ, Zajicke JP, Thompson AJ. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 2007;6:1094-1105.
7. Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al, for the Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Myasthenia Gravis: recommendations for clinical research standards. Neurology 2000;55:16-23.
8. Lindblad AS, Clemons T, Lindblad RW, Sykes R, Meador KJ, Odenkirchen JC, et al. Applicability of NINDS-sponsored studies to community-based physician involvement. Neurology 2008;70:1688-1690.
9. Mullins LL, Carpentier MY, Paul RH, Sanders DB and the Muscle Study Group. A disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve 2008 (to be published).
10. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394-399.
11. Padua L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 2001;22:363-369.
12. Palace J, Newsom-Davis J, Lecky B and the Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998;50:1778-1783.
13. Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann N Y Acad Sci 2003;998:440-444.
14. Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MHV, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:400-406.
15. Sharshar T, Chevret S, Mazighi M, et al. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol 2000;247:286-290.
16. Shy ME, Chen L, Swan ER, et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008;70:378-383.
17. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999;52:1487-1489.